Biomimetic Therapeutics Inc

Biomimetic Therapeutics — 2010 AOFAS Annual Summer Meeting

19 slides from Biomimetic Therapeutics's conference presentation, Jul 7, 2010

  1. Slide 1: North American Pivotal Trial Review

    Slide 1: North American Pivotal Trial Review

    North American Pivotal Trial Review Outcomes of a Randomized, Controlled, Trial to Evaluate Augment Bone Graft (rhPDGF-BB/ß-TCP) as a Replacement for Autograft in Hindfoot and Ankle Fusion 2010 AOFAS Annual Summer Meeting Washington, DC Presented By: Tim Daniels, MD – Toronto, ON

  2. Slide 2: Disclosure

    Slide 2: Disclosure

    Disclosure Disclosures available on AOFAS Meeting Book In the United States, Augment Bone Graft is an investigational product and is not available for sale In Canada, Augment Bone Graft is an approved Class IV medical device and is indicated as a replacement for autograft in ankle, hindfoot and midf

  3. Slide 3: Augment Bone Graft (rhPDGF-BB/ß-TCP)

    Slide 3: Augment Bone Graft (rhPDGF-BB/ß-TCP)

    Augment™ Bone Graft ( rhPDGF-BB/ß-TCP) Developed as a fully synthetic replacement for autograft Recombinant PDGF (rhPDGF-BB) FDA approved for tissue regeneration periodontal bone defects (GEM 21S ® ) diabetic foot ulcers (Regranex ® ) Prior Studies in Orthopedics pilot studies: foot/ankle, wrist

  4. Slide 4: Pivotal Trial Objectives

    Slide 4: Pivotal Trial Objectives

    Pivotal Trial Objectives HYPOTHESIS : Augment Bone Graft (rhPDGF-BB/ß-TCP) is non-inferior to autograft when used as a healing adjunct during hindfoot and ankle fusion surgery PRIMARY ENDPOINT : % patients fused by CT scan at 6 months, defined as ≥50% osseous bridging across the joint surface (per C

  5. Slide 5: Study Protocol

    Slide 5: Study Protocol

    Study Protocol 2:1 randomization, Augment™ (rhPDGF-BB/ß-TCP): Autograft Autograft from iliac crest, Gerdy’s, distal tibia, calcaneus Std joint preparation, ORIF using ≤ 3 screws/joint Post-op immobilization for 12 wks, NWB first 6 wk CT evaluation: 9, 16, 24, 36 wks XR evaluation: 1-3, 6, 9, 12, 16,

  6. Slide 6: Largest clinical study ever performed in foot and ankle patients

    Slide 6: Largest clinical study ever performed in foot and ankle patients

    Largest clinical study ever performed in foot and ankle 434 patients 37 clinical centers (USA/CAN) 72 investigators First of its kind with a recombinant protein Study Scope

  7. Slide 7: Study Demographics

    Slide 7: Study Demographics

    Study Demographics All Patients n= 434 Augment™ n= 285 Autograft n=149 Sex (M/F) 49.8% / 49.1% 46.3% / 52.3% 56.4% / 43.0% Age (Mean) 56.6 years 56.2 years 57.5 years BMI (Mean) 30.8 30.7 31.1 Diagnosis Post Traumatic OA 48.2% 48.8% 47.0% Primary Arthritis 34.3% 32.6% 37.6% Rheumatoid 6.7% 8.4% 3.4%

  8. Slide 8: Clinical Example, Ankle

    Slide 8: Clinical Example, Ankle

    Clinical Example, Ankle

  9. Slide 9: Radiographic Assessment

    Slide 9: Radiographic Assessment

    Radiographic Assessment 3 months Post-op Radiographs and clinical evaluation useful but not always reliable

  10. Slide 10: CT Assessment

    Slide 10: CT Assessment

    CT Assessment 6 weeks Post-op Multiple areas of Osseous-bridging

  11. Slide 11: Patient Accountability

    Slide 11: Patient Accountability

    Patient Accountability Screened Population n=457 (456*) *Less one subject screened twice Randomized Population n=435 ITT Population n=434 Augment (285)/Autograft (149) mITT Population n=397 Augment (260)/Autograft (137) Not randomized n=21 Not randomized prior to treatment n=1 Excluded from mITT n=1

  12. Slide 12: Radiographic Endpoints - 36/52 wks

    Slide 12: Radiographic Endpoints - 36/52 wks

    Radiographic Endpoints -36/52 wks Augment N=260 Joints=394 Autograft N=137 Joints=203 Non- Inferiority (p-value) CT Fusion - 36 wks Full Complement of Joints 63.5% 69.3% No (0.202) All Joints 68.8% 73.9% No (0.103) XR Fusion (3 views) - 52 wks Full Complement of Joints 36.9% 36.5% Yes (0.020) All Jo

  13. Slide 13: Radiographic Endpoints

    Slide 13: Radiographic Endpoints

    Radiographic Endpoints – 24 wks Augment N=260 Joints=394 Autograft N=137 Joints=203 Non- Inferiority (p-value) CT Fusion Rate Full complement of joints 61.2% 62.0% Yes (0.038) All joints 66.5% 62.6% Yes (<0.001) XR Fusion (3 views) Full complement of joints 30.8% 32.8% No (0.054) All joints 38.3% 37

  14. Slide 14: Radiographic Endpoints - 36/52 wks

    Slide 14: Radiographic Endpoints - 36/52 wks

    Radiographic Endpoints - 36/52 wks Augment N=260 Joints=394 Autograft N=137 Joints=203 Non- Inferiority (p-value) CT Fusion - 36 wks Full Complement of Joints 63.5% 69.3% No (0.202) All Joints 68.8% 73.9% No (0.103) XR Fusion (3 views) - 52 wks Full Complement of Joints 36.9% 36.5% Yes (0.020) All J

  15. Slide 15: Clinical Endpoints

    Slide 15: Clinical Endpoints

    Clinical Endpoints – 52 wks Augment N=260 Joints=394 Autograft N=137 Joints=203 Non-Inferiority (p-value) Clinical Healing (Investigator Assessed) Patient Level 87.7% 88.3% Yes (0.003) Full complement of joints 86.2% 87.6% Yes (0.008) All joints 88.3% 87.2% Yes (<0.001) Nonunion 4.2% 5.8% Yes (<0.00

  16. Slide 16: Functional Endpoints

    Slide 16: Functional Endpoints

    Functional Endpoints – 52 wks Augment N=260 Autograft N=137 Non- Inferiority (p-value) SF-12 (Mean PCS) 42.4 45.0 Yes (<0.001) Foot Fusion Index (Mean Total) 20.1 17.5 Yes (0.012) AOFAS Ankle-Hindfoot Scale 77.8 78.2 Yes (<0.001) VAS Pain Scores Fusion Site 13.2 12.9 Yes (<0.001) Weight Bearing 15.6

  17. Slide 17: Safety Endpoints

    Slide 17: Safety Endpoints

    Safety Endpoints – 52 wks Augment N=272 Autograft N=142 P-value (Fisher Exact Test) Serious Treatment Emergent AE’s 10.3% 14.8% No difference (0.201) Complications (Surgically Related) 23.9% 30.3% No difference (0.195) Complications (Serious) 5.1% 6.3% No difference (0.654) Infections 8.5% 11.3% No

  18. Slide 18: Pivotal Trial Data Summary

    Slide 18: Pivotal Trial Data Summary

    Pivotal Trial Data Summary Augment Bone Graft met the primary endpoint of the study – statistically significant non-inferiority to autograft per CT fusion rate at 24 wks 52 wk non-union rate ( 4.2% augment vs 5.8% autograft) is consistent with the published literature, despite high percentage of pat

  19. Slide 19: Discussion/Conclusions

    Slide 19: Discussion/Conclusions

    Discussion/Conclusions Harvesting autograft is a time-consuming procedure; which is associated with potential complications and prolonged post- operative patient pain Augment Bone Graft treated patients experienced fewer serious adverse events and were spared the pain and morbidity of bone graft har

Source: SEC EDGAR · 8-K filed Jul 7, 2010

More decks from Biomimetic Therapeutics Inc